Know Cancer

or
forgot password

Program for Assessment of Activity and Safety of 1st-line Bevacizumab (Avastin) Therapy in Elderly Patients With Metastatic Colorectal Cancer (BEVERLY-C Study)


N/A
65 Years
N/A
Not Enrolling
Both
Colorectal Cancer

Thank you

Trial Information

Program for Assessment of Activity and Safety of 1st-line Bevacizumab (Avastin) Therapy in Elderly Patients With Metastatic Colorectal Cancer (BEVERLY-C Study)


Inclusion Criteria:



- Adult patients, >/= 65 years of age

- Patients with newly diagnosed metastatic colorectal cancer starting first-line
treatment with Avastin in combination with fluoropyrimidine-based chemotherapy
according to the approved Hungarian Summary of Product Characteristics

- Patients suitable for Avastin treatment as assessed by the treating physician

Exclusion Criteria:

- Any contraindications to Avastin treatment according to the Hungarian Summary of
Product Characteristics

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Median progression-free survival

Outcome Time Frame:

approximately 3.5 years

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

Hungary: Medical Research Council

Study ID:

ML25630

NCT ID:

NCT01791140

Start Date:

March 2011

Completion Date:

May 2011

Related Keywords:

  • Colorectal Cancer
  • Colorectal Neoplasms

Name

Location